[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365653-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-365653-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","molecular-prognostic-factors-in-uterine-serous-carcinomas-a-systematic-review","Molecular Prognostic Factors in Uterine Serous Carcinomas - A Systematic Review","","Uterine serous carcinomas are an aggressive minority of endometrial cancers, defined by TP53 mutations and extensive copy number alterations, and grouped in the copy number-high/p53abn molecular prognostic category with a distinct molecular profile. Biomarker-based molecular categorization supports treatment selection and is widely used in clinical settings. This systematic review identifies molecular characteristics with prognostic significance to guide therapy needs, using English-language evidence from PubMed/Medline and Cochrane databases through February 2025.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/molecular-prognostic-factors-in-uterine-serous-carcinomas-a-systematic-review/365653/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/molecular-prognostic-factors-in-uterine-serous-carcinomas-a-systematic-review/365653.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What molecular features characterize uterine serous carcinomas in this review?","Question",{"text":63,"@type":64},"They are associated with TP53 mutations and extensive copy number alterations, placing them primarily in the copy number-high/p53abn molecular prognostic group.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the systematic review search for relevant studies?",{"text":68,"@type":64},"It uses a bibliographic search in PubMed/Medline and Cochrane databases with PRISMA-guided keywords for prognostic factors in (serous) endometrial or uterine cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"How many studies and molecular characteristics were identified?",{"text":72,"@type":64},"The review included 95 studies and identified 66 distinct molecular characteristics, including new cancer signatures potentially affecting prognosis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},365653,1790420727,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Systematic Review  \nMolecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review  \nAnna Svarna *, Michalis Liontos , Alkistis Papatheodoridi , Aristea-Maria Papanota , Eleni Zografos , Maria Kaparelou, Flora Zagouri  and Meletios-Athanasios Dimopoulos   \nReceived: 23 February 2025  \nRevised: 5 April 2025  \nAccepted: 22 April 2025  \nPublished: 25 April 2025  \nCitation: Svarna, A.; Liontos, M.; Papatheodoridi, A.; Papanota, A.-M.; Zografos, E.; Kaparelou, M.; Zagouri, F.; Dimopoulos, M.-A. Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review.  \nCurr. Oncol. 2025, 32, 251. [https://](https://)[ ](https://)[doi.org/10.3390/curroncol32050251](doi.org/10.3390/curroncol32050251)  \n[Copyright:](Copyright:) © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \nDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital,  \nV.Sofias 80, 11528 Athens, Greece; mliontos@gmail.com (M.L.); alkistispapath@gmail.com (A.P.); [ampapanota@yahoo.gr](ampapanota@yahoo.gr) (A.-M.P.); [el_zogra@hotmail.com](el_zogra@hotmail.com) (E.Z.); [mkaparelou@yahoo.com](mkaparelou@yahoo.com) (M.K.); florazagouri@yahoo.co.uk (F.Z.); mdimop@med.uoa.gr (M.-A.D.)  \n* Correspondence: [anna.svarna@hotmail.com](anna.svarna@hotmail.com); Tel.: +30-2132162845  \nAbstract: Uterine serous carcinomas are an aggressive minority of endometrial cancers. They are characterized by mutations in TP53 and extensive copy number alterations and are primarily classified in the copy number-high/p53abn molecular prognostic group, highlighting a unique molecular profile that is crucial for understanding their behavior and treatment responses. Clinical studies have shown that molecular categorization via biomarkers can facilitate proper treatment selection, and this is now widely used. In this context, the scope of this systematic review is to identify molecular characteristics with prognostic significance for these neoplasms to further inform on their treatment needs. We performed a comprehensive literature search of all articles written in English using the PubMed/Medline and Cochrane databases through February 2025 . Our review led to the inclusion of 95 studies, from which we identified a total of 66 distinct molecular characteristics along with new cancer signatures that may impact prognosis. These findings have the potential to inform clinical practice by aiding in the development of tailored treatment strategies for patients with uterine serous carcinoma, ultimately improving outcomes in this challenging malignancy.  \nKeywords: serous uterine cancer; prognostic factors; biomarkers  \n1. Introduction  \nEndometrial cancer is the most common gynecological malignancy in developed countries. In 2025, it is predicted that more than 69,000 women will be diagnosed with the disease in the United States alone. Uterine Serous Carcinomas (USC) constitute a subset of endometrial carcinomas, diagnosed in about 10% of cases. USCs are characterized by diagnosis at a more advanced stage, common recurrences outside the pelvis, and worse prognosis [1–3]. USCs, along with other high-grade histologies, were historically classified as type 2 endometrial carcinomas in distinction to low-grade endometrial carcinomas that were designated as type 1 lesions.  \nNowadays, the classification of endometrial carcinomas has advanced through the comprehensive molecular analysis performed by The Cancer Genome Atlas (TCGA), recognizing four subtypes with specific molecular characteristics: POLE ultra-mutated, microsatellite instability hyper-mutated, copy-number low, and copy-number high [4] . In clinical practice, though, it is more common and accessible to test f","cbCaifGVodI6Ys4h","https://ap.wps.com/l/cbCaifGVodI6Ys4h","pdf",709455,23,"English","# Introduction\n## Endometrial cancer classification and molecular subtypes\n## Role of molecular classification in risk stratification and therapy\n# Materials and Methods\n## Literature search strategy and databases\n## Screening process and study selection","[{\"question\":\"What molecular features characterize uterine serous carcinomas in this review?\",\"answer\":\"They are associated with TP53 mutations and extensive copy number alterations, placing them primarily in the copy number-high/p53abn molecular prognostic group.\"},{\"question\":\"How does the systematic review search for relevant studies?\",\"answer\":\"It uses a bibliographic search in PubMed/Medline and Cochrane databases with PRISMA-guided keywords for prognostic factors in (serous) endometrial or uterine cancer.\"},{\"question\":\"How many studies and molecular characteristics were identified?\",\"answer\":\"The review included 95 studies and identified 66 distinct molecular characteristics, including new cancer signatures potentially affecting prognosis.\"}]","Molecular Prognostic Factors in Uterine Serous Carcinomas - A Systematic Review | PDF",1790161607,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96ab01c3ce44cd513e697e9cf5b887ff.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d990a29ec17436b3262da95dbec2361d.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6af61293604fdf6b1c0bcfad84882fd1.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/208404d1de82dd5e13c778b1cb9f3f60.webp",980,1385]